Cognitive
Davunetide
Also called NAP, AL-108, AL-208
per administration
It has been used in people, but no trial has settled how much or how often.
The human evidence for Davunetide used the intranasal route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Davunetide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 5–15 mg per administration
- How often
- Twice a day
- Where
- Intranasal spray
- Time to steady level
- ~5 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Davunetide describe 5–15 mg per administration. Descriptive only, not a recommendation.
A short octapeptide; human plasma pharmacokinetics are limited and estimates are rough.
Reached phase 2 as an intranasal spray (the AL-108 program in mild cognitive impairment and progressive supranuclear palsy) and was also given intravenously (AL-208); the larger trials did not meet their primary endpoints and no effective dose-ranging schedule was established, so no schedule table is shown.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 5hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Davunetide (AL-108/AL-208) phase-2 programAn intranasal NAP octapeptide taken through phase 2 for progressive supranuclear palsy and cognition; primary endpoints were not met.